相似文献/References:
[1]张素荣,袁 宇,赵国安,等.阿替洛尔对急性心肌梗死Q - T 及Q - Tc 离散度的影响[J].新乡医学院学报,2003,20(02):117.
[2]李明琰,滕清雷,高红艳.心肌缺血预适应对初次急性心肌梗死患者临床及近期预后的影响[J].新乡医学院学报,2006,23(01):000.
[3]许春玲.尿激酶溶栓治疗老年急性心肌梗死的观察及护理[J].新乡医学院学报,2008,25(01):090.
[4]范颖英.急性心肌梗死早期溶栓治疗观察与护理[J].新乡医学院学报,2009,26(01):093.
[5]赵冬太,李雪梅.重组组织型纤溶酶原激活剂治疗发病4.5~9.0 h脑梗死的有效性及安全性[J].新乡医学院学报,2019,36(9):872.[doi:10.7683/xxyxyxb.2019.09.016]
ZHAO Dong-tai,LI Xue-mei.Efficacy and safety of recombinant tissue plasminogen activator in the treatment of cerebral infarction within 4.5-9.0 hours[J].Journal of Xinxiang Medical University,2019,36(01):872.[doi:10.7683/xxyxyxb.2019.09.016]
[6]钱时德,赵 全,焦冬生,等.依达拉奉联合重组组织型纤溶酶原激活剂静脉溶栓治疗急性脑梗死疗效观察[J].新乡医学院学报,2020,37(11):1040.[doi:10.7683/xxyxyxb.2020.11.008]
QIAN Shide,ZHAO Quan,JIAO Dongsheng,et al.Effect of edaravone combined with recombinant tissue type plasminogen activator intravenous thrombolysis in the treatment of acute cerebral infarction[J].Journal of Xinxiang Medical University,2020,37(01):1040.[doi:10.7683/xxyxyxb.2020.11.008]